The Claim

Took executive action to expand access to in vitro fertilization (IVF).

The Claim, Unpacked

What is literally being asserted?

That the administration signed an executive order related to IVF access. This is narrowly true: on February 18, 2025, President Trump signed Executive Order 14216, “Expanding Access to In Vitro Fertilization.”

What is being implied but not asserted?

The phrasing “expand access” implies that IVF became more accessible as a result of this action — that the executive order itself produced a tangible change in Americans’ ability to obtain or afford IVF treatment. In context alongside 364 other “wins,” it implies mission accomplished.

What is conspicuously absent?

The claim omits nearly everything material: that the EO’s sole operative provision was a directive to produce policy recommendations within 90 days; that it created no mandates, no funding, no enforceable rights; that it fell dramatically short of Trump’s campaign promise to have “government or insurance companies” pay for IVF; that the same party’s senators blocked the Right to IVF Act twice in 2024; that IVF coverage was stripped from the FY2026 NDAA during Republican-led conference negotiations; and that the administration’s own allies in state legislatures were advancing personhood laws that directly threaten IVF practice.

Evidence Assessment

Established Facts

Executive Order 14216 was signed on February 18, 2025, and published in the Federal Register on February 24, 2025. ¹ The order’s sole operative section directed the Assistant to the President for Domestic Policy to submit “a list of policy recommendations on protecting IVF access and aggressively reducing out-of-pocket and health plan costs for IVF treatment” within 90 days. Section 3 explicitly states the order “is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party.”

During the 2024 campaign, Trump promised far more than an executive order requesting recommendations. ² In August 2024, he told audiences: “Your government will pay for — or your insurance company will be mandated to pay for — all costs associated with IVF treatment.” This was a specific pledge of either government funding or an insurance mandate. The executive order contains neither.

Senate Republicans blocked the Right to IVF Act twice in 2024. ³ In June and September 2024, the bill — which would have established a nationwide right to IVF access, expanded veteran fertility benefits, and increased affordability — failed to advance on largely party-line votes (51-44 in September). Only Republican Senators Collins (R-ME) and Murkowski (R-AK) voted in favor. Republican leadership dismissed the bill as a “political stunt.”

IVF coverage was stripped from the FY2026 NDAA during conference negotiations. ⁴ Both the House and Senate versions of the FY2026 National Defense Authorization Act included provisions for TRICARE to cover three IVF cycles for military families. House Speaker Mike Johnson removed the provision during closed-door conference negotiations. TRICARE continues to exclude IVF and IUI except in rare cases of documented service-related infertility. One in four military members experience infertility — higher than the general population.

The Alabama Supreme Court’s February 2024 ruling in LePage v. Center for Reproductive Medicine declared frozen embryos are “children” under state law. ⁵ This ruling caused IVF clinics across Alabama to pause services, demonstrating how personhood frameworks directly threaten IVF practice. The state legislature passed narrow liability protection to allow services to resume, but the underlying legal theory remains intact. During the 2024 legislative session, more than 40 bills with personhood language were proposed in 16 states. At least nine existing state laws are broad or vague enough to put IVF services at risk. EO 14216 does not address the personhood threat to IVF.

The follow-up actions announced October 16, 2025, were modest in scope. ⁶ Eight months after the EO, the administration announced three initiatives: (1) a drug discount agreement with EMD Serono offering 84% off list prices when three specific medications (Gonal-f, Ovidrel, Cetrotide) are bundled; (2) tri-agency guidance from DOL, HHS, and Treasury clarifying that employers can offer fertility benefits as “excepted benefits” outside major medical insurance; and (3) expedited FDA review of Pergoveris, a combination fertility therapy. In February 2026, the TrumpRx.gov platform launched offering reduced pricing on these fertility drugs.

Strong Inferences

The drug discount and excepted benefits guidance address only a fraction of IVF costs. ⁷ KFF estimates the medication discounts could save “up to $2,200 per cycle” on drugs that normally cost over $5,000 — but the bulk of IVF expenses are procedural: egg retrieval, embryo transfer, genetic testing, and monitoring, which total $15,000-$20,000 per cycle. The excepted benefits pathway allows employers to offer standalone fertility coverage or a limited HRA capped at $2,150 per year — far below a single cycle’s cost. Critically, participation is entirely voluntary, with no mandates, subsidies, or tax incentives to encourage employer adoption. ASRM characterized the $2,150 HRA cap as “far below the full cost of an IVF cycle.”

The excepted benefits framework may actually weaken consumer protections for those who do receive fertility coverage. ⁸ Excepted benefits are exempt from ACA consumer protections — no essential health benefits requirements, no out-of-pocket maximums, no prohibition on annual or lifetime limits. KFF noted this pathway “technically existed since 1996 but lacked explicit regulatory guidance.” The administration’s contribution was regulatory clarification, not the creation of new coverage pathways. Benefits experts noted the announcement is “unlikely to encourage new employers or insurers to offer fertility benefits.”

The gap between campaign rhetoric and executive action is substantial. ⁹ The campaign promise was government payment or insurance mandates for “all costs associated with IVF.” The executive order delivered a request for policy recommendations. The follow-up actions delivered voluntary drug discounts and optional employer guidance. No legislation has been proposed by the administration. No mandate exists. ASRM noted the initiative lacks mechanisms ensuring access for “low-income individuals, Medicaid beneficiaries, people in rural communities, and LGBTQIA+ individuals.” Nearly 16 million reproductive-age Medicaid enrollees remain unaffected.

Federal employees already had better IVF access than what the EO produced for the general public. ¹⁰ Beginning in plan year 2025, FEHB carriers including Blue Cross Blue Shield and GEHA began offering comprehensive IVF coverage with $25,000 annual benefits. By 2026, OPM mandated that HMO plans in states with IVF coverage laws must meet those requirements, producing the highest number of IVF-covering plans in FEHB history. Members of Congress and their staff already had IVF coverage. This expansion was initiated by OPM in 2024, before Trump took office.

What the Evidence Shows

The literal claim is true: the administration did take executive action on IVF. Executive Order 14216 exists, it was signed, and it references expanding IVF access. Subsequent actions in October 2025 and February 2026 produced some concrete — if narrow — results in the form of drug discounts and regulatory clarification.

But the framing of this as a “win” requires ignoring the overwhelming gap between what was promised, what was delivered, and what was simultaneously undermined. Trump’s campaign promise was that the government or insurance companies would pay for all IVF costs. The executive order requested a list of recommendations. The follow-up produced voluntary drug discounts covering a fraction of per-cycle costs, and regulatory guidance for an optional employer benefit pathway that had technically existed for decades.

Meanwhile, the same political coalition that signed EO 14216 blocked the Right to IVF Act twice in the Senate, stripped IVF coverage from the defense bill during conference, and continued to advance personhood legislation in state legislatures that poses the single greatest legal threat to IVF practice in the United States. The executive order does not mention personhood, does not establish any right to IVF, and does not mandate coverage by any insurer. It explicitly disclaims creating “any right or benefit, substantive or procedural, enforceable at law or in equity.”

The structural pattern is familiar from other items in this section: an executive order announces an intention, follow-up actions produce modest voluntary programs, while legislative opportunities to create enforceable rights are blocked. The announcement creates the impression of action; the fine print reveals the action is a request to study the problem; the legislative record shows the party in power actively opposing the binding solutions that would address it.

The Bottom Line

The executive order is real. The drug discounts are real, if narrow. But calling this “expanding access to IVF” overstates what the administration accomplished and obscures what it chose not to do. An executive order that produces no enforceable rights, no coverage mandates, and no new funding — issued by a president who promised government-paid IVF, whose party blocked IVF legislation twice, and whose allies stripped IVF coverage from the defense bill — is better understood as a political gesture than a healthcare expansion. The verdict is true but misleading: the executive action was taken, but the access it “expanded” remains largely theoretical.

Footnotes

1. Federal Register, “Executive Order 14216 — Expanding Access to In Vitro Fertilization,” 90 FR No. 35, February 24, 2025. https://www.federalregister.gov/documents/2025/02/24/2025-03064/expanding-access-to-in-vitro-fertilization ↩

2. NBC News, “Trump says he wants to make IVF treatments paid for by government or insurance companies,” August 29, 2024. https://www.nbcnews.com/politics/donald-trump/trump-says-wants-make-ivf-treatments-paid-government-insurance-compani-rcna168804 ↩

3. NPR, “Senate Republicans block Democrats’ bill ensuring access to IVF,” September 17, 2024. https://www.npr.org/2024/09/17/g-s1-23414/senate-republicans-block-ivf-legislation ↩

4. National Military Family Association, “NMFA Condemns Removal of IVF Coverage for Military Families in Final FY26 NDAA,” December 8, 2025. https://www.militaryfamily.org/nmfa-condemns-removal-of-ivf-coverage-for-military-families-in-final-fy26-ndaa/ ↩

5. LePage v. Center for Reproductive Medicine, P.C., Alabama Supreme Court, Case No. SC-2022-0579, decided February 16, 2024. https://law.justia.com/cases/alabama/supreme-court/2024/sc-2022-0579.html ; NPR, “How ‘fetal personhood’ in Alabama’s IVF ruling evolved from fringe to mainstream,” March 14, 2024. https://www.npr.org/2024/03/14/1238102768/fetal-personhood-alabama-ivf ↩

6. U.S. Department of Labor, “Labor Secretary applauds President Trump’s actions to expand IVF access,” October 16, 2025. https://www.dol.gov/newsroom/releases/osec/osec20251016 ; CMS, “FAQs About Affordable Care Act Implementation Part 72,” October 16, 2025. https://www.cms.gov/files/document/faqs-part-72.pdf ↩

7. Kaiser Family Foundation, “Will Trump’s Announcement Expand Access to IVF?” October 2025. https://www.kff.org/womens-health-policy/will-trumps-announcement-expand-access-to-ivf/ ; ASRM, “Evaluating the Trump Administration’s Initiative on IVF.” https://www.asrm.org/advocacy-and-policy/fact-sheets-and-one-pagers/evaluating-the-trump-administrations-initiative-on-ivf/ ↩

8. CMS, “FAQs About Affordable Care Act Implementation Part 72,” October 16, 2025. https://www.cms.gov/files/document/faqs-part-72.pdf ; KFF analysis notes excepted benefits lack ACA consumer protections. ↩

9. NBC News campaign coverage (August 2024); Segal Consulting, “Will IVF Access and Cost Change in 2025?” https://www.segalco.com/consulting-insights/executive-order-on-ivf ; ASRM evaluation. ↩

10. Federal News Network, “FEHB enrollees will see more choices for comprehensive IVF coverage in 2025,” September 2024. https://federalnewsnetwork.com/benefits/2024/09/fehb-enrollees-will-see-more-choices-for-comprehensive-ivf-coverage-in-2025/ ↩